The USFDA stated that Goa facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed.
from Latest News http://bit.ly/2K3sM1v
Monday, 27 May 2019
Lupin slips 5% as USFDA classifies Goa facility's inspection as OAI
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment